<DOC>
	<DOCNO>NCT01458210</DOCNO>
	<brief_summary>The purpose study look body process oral contraceptive ( OC ) , use Ortho-Cyclen , commonly prescribe combination oral contraceptive healthy female participant , effect dulaglutide Ortho-Cyclen process body . Information side effect may occur also collect .</brief_summary>
	<brief_title>A Study Effect Dulaglutide How Body Handles Oral Contraceptive Healthy Female Participants</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Are females childbearing potential , overtly healthy determine medical history physical examination As possible dulaglutide may cause oral contraceptive ( OC ) tablet less effective usual , participant require use 2 additional highly effective method contraception screen appointment 2 month poststudy followup appointment . Additional method contraception may include follow : nonhormonal intrauterine device spermicide ; male female condom spermicide ; contraceptive sponge spermicide ; diaphragm spermicide ; cervical cap spermicide ; sterile sexual partner ; abstinence ( participant report abstinence become sexually active study must agree use additional method contraception ) . The pregnancy test result must negative screen checkin Have body mass index ( BMI ) 18.5 30.0 kilogrammeter square ( kg/m^2 ) , screen Have clinically significant finding , determine investigator , upon bimanual pelvic breast examination , screen ( provision previous gynecological examination documentation may accept ) Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sampling Are reliable willing make available duration study willing follow study procedure restriction Have give write informed consent approve Lilly ethical review board ( ERB ) govern site Are currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product , concurrently enrol type medical research judge scientifically medically compatible study Have know allergy OrthoCyclen , dulaglutide , related compound component either formulation Are persons previously complete withdrawn study study investigate dulaglutide within 3 month prior screen receive glucagonlike peptide incretin mimetics 3 month prior screen Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have abnormal blood pressure ( BP ) ( least 5 minute sit ) , opinion investigator , increase risk associate participate study Have history presence respiratory , hepatic , renal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have history presence cardiovascular disorder ( include myocardial infarction , cerebrovascular accident , coronary artery disease , venous thromboembolism , arrhythmia [ judge investigator clinically significant ] , angina ) within last year , symptom sign congestive heart failure , expect require coronary artery bypass surgery angioplasty Have history presence pancreatitis ( history chronic pancreatitis idiopathic acute pancreatitis ) gastrointestinal disorder , example relevant esophageal reflux gall bladder disease , gastrointestinal disease impact gastric empty ( GE ) ( , gastric bypass surgery , pyloric stenosis , exception appendectomy ) could aggravate glucagonlikepeptide 1 ( GLP1 ) analog . Participants dyslipidemia , participant cholecystolithiasis ( removal gall stone ) and/or cholecystectomy ( removal gall bladder ) past , sequela , may include study discretion screen physician Show evidence significant active neuropsychiatric disease Have family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus ( HIV ) infection and/or positive HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Are woman positive pregnancy test woman lactate Have use intend use St John 's Wort within 21 day study drug administration unable/unwilling adhere study drug restriction Have donate blood 500 milliliter ( mL ) within last month prior admission leadin phase Have average weekly alcohol intake exceed 14 unit per week , unwilling stop alcohol consumption 48 hour prior admission clinical research unit ( CRU ) resident CRU ( 1 unit = 12 ounce [ oz ] 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Use tobacco nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) within 6 month prior admission leadin phase Have take injectable contraceptive use hormonal implant within 12 month enrollment study topical control delivery contraceptive ( patch ) hormonal intrauterine device ( , MirenaÂ® device ) within 3 month prior enrollment study The history presence contraindication combine OC tablet include thrombosis history thromboembolic disease , recurrent jaundice , acute chronic liver disease , migraine , undiagnosed vaginal bleeding , significant hyperlipidemia , hepatic adenoma , mammary , endometrial , hepatic carcinoma estrogendependent neoplasia ( know suspect ) In opinion investigator sponsor , unsuitable inclusion study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>